But, as I said earlier, from a Teleflex perspective, at least for the next number of years, our goal is to bring a better technology to the gastric sleeve market, which none of us think is going away. It might be a little bit smaller, but it’s not going away and there’s still ample market for us to grow into as a company. So, I still think that even though standard has not had the start we would have wanted it to have, I still think it’s going to be, longer term, a nice growth driver for Teleflex, and it’s going to grow into the market. And by the time we get to our penetration point, we’ll see what’s happening with GLP-1s, whether it was an air pocket or not. I think, more broadly, what I’m more encouraged by is that 98% of Teleflex’s – 98% plus percent of Teleflex’s portfolio has no impact from GLP-1.
So, I think, investors are probably branding everybody as GLP-1 impacted right now just because of all the hype about it. But as you break down the different company components and what we know right now, we can see it as 98% plus of our company not impacted.
Operator: Your next question comes from the line of Matthew O’Brien with Piper Sandler. Your line is open.
Samantha: Hi. This is Samantha on for Matt. A quick question from us on the MSAs. What do you think – you talked a little bit about financials on the topline, but what about the potential of lost revenue on both top and bottom line?
Liam Kelly: So, from the – just to be clear, the MSA, the manufacturing service agreement?
Samantha: Yes, that’s right.
Liam Kelly: Okay. So, as Tom said in his prepared remarks, the early close will lose about $4 million in revenue. From an EPS impact, it’s around $0.01 or thereabout.
Thomas Powell: Very minimal.
Liam Kelly: Minimal, yes. So, it’s around – it’s fairly minimal from an EPS perspective, this year, and most investors will know that the MSA has now gone completely, and there was around $70 million in revenue in a full year and around $0.25 in earnings in a full year. So, that will help individuals with their modeling. So, I think the greater impact to earnings per share in this year is, obviously, the early close of Palette, which costs around $0.10. And then FX has cost us, Tom, I think another approximately $0.05 or thereabout?
Thomas Powell: That’s correct.
Liam Kelly: Okay.
Samantha: That’s perfect. Thank you so much.
Operator: Your next question comes from the line of Craig Bijou with Bank of America Securities. Your line is open.
Craig Bijou: Good morning. Thanks for taking the questions. I know we’re at the end, so I’ll keep it to one topic. Wanted to ask on MANTA. Liam, I think you mentioned it in your prepared remarks. I don’t think we’ve talked about it in a while. So, just wanted to see, you know, some of the strength there? Was it the recovery in the procedures that MANTA is used in or are you seeing better adoption? And then maybe just some comments on how MANTA will contribute to your growth as part of your long-term plan or over the next couple of years?
Liam Kelly: Yes. So, MANTA is obviously launching in many jurisdictions and geographies, right now. We saw some nice strength as we’ve gone through the three quarters in Asia. And we believe it will be a multiyear driver for us, Craig. It’s a unique product. It’s – I don’t think we’re gaining honestly from any type of surge – any type of procedural rebound, because we’re still penetrating the market, still bringing it to new customers. And the uniqueness of the product, it still gives us a significant benefit and it will be a multiyear driver for us. We’re absolutely – within the high-growth portfolio, if you look at it, you’ve got some really nice products within their, you’ve got MANTA, you’ve got the Vidacare portfolio, you got our PICCs, you got Z-Medica.
You’ve got Titan that had a little bump along the road. You got UroLift that had a bump, but now you’ve got Barrigel and the whole Palette and interventional urology within that high growth. So, feel really good about MANTA. And I suppose you’re right. It doesn’t get as much attention as it used to when it started its journey.
Craig Bijou: Thanks.
Operator: That is all the time we have for questions this morning. Our conference call for today is now concluded. Thank you all for your participation. You may now disconnect.
